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The dual S1PR1/S1PR5 drug BAF312
(Siponimod) attenuates demyelination in
organotypic slice cultures
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Abstract
Background: BAF312 (Siponimod) is a dual agonist at the sphingosine-1 phosphate receptors, S1PR1 and S1PR5.
This drug is currently undergoing clinical trials for the treatment of secondary progressive multiple sclerosis (MS).
Here, we investigated the effects of BAF312 on isolated astrocyte and microglia cultures as well as in slice culture
models of demyelination.
Methods: Mouse and human astrocytes were treated with S1PR modulators and changes in the levels of pERK,
pAkt, and calcium signalling as well as S1PR1 internalization and cytokine levels was investigated using Western
blotting, immunochemistry, ELISA and confocal microscopy. Organotypic slice cultures were prepared from the
cerebellum of 10-day-old mice and treated with lysophosphatidylcholine (LPC), psychosine and/or S1PR modulators,
and changes in myelination states were measured by fluorescence of myelin basic protein and neurofilament H.
Results: BAF312 treatment of human and mouse astrocytes activated pERK, pAKT and Ca2+ signalling as well as
inducing S1PR1 internalization. Notably, activation of S1PR1 increased pERK and pAKT in mouse astrocytes while
both S1PR1 and S1PR3 equally increased pERK and pAKT in human astrocytes, suggesting that the coupling of
S1PR1 and S1PR3 to pERK and pAKT differ in mouse and human astrocytes. We also observed that BAF312 moderately
attenuated lipopolysaccharide (LPS)- or TNFα/IL17-induced levels of IL6 in both astrocyte and microglia cell cultures. In
organotypic slice cultures, BAF312 reduced LPC-induced levels of IL6 and attenuated LPC-mediated demyelination. We
have shown previously that the toxic lipid metabolite psychosine induces demyelination in organotypic slice cultures,
without altering the levels of cytokines, such as IL6. Importantly, psychosine-induced demyelination was also attenuated
by BAF312.
Conclusions: Overall, this study suggests that BAF312 can modulate glial cell function and attenuate demyelination,
highlighting this drug as a further potential therapy in demyelinating disorders, beyond MS.
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Background
The family of spingosine-1-phosphate receptors (S1PR)
have been rapidly gaining attention as important mediators
of many cellular processes, including cell differentiation,
migration, survival, angiogenesis, calcium homeostasis,
inflammation and immunity [1]. These receptors are G-
protein coupled and are known targets for the drug
Gilenya® (pFTY720), an oral therapy used in patients with
multiple sclerosis (MS) [2]. The phosphorylated version of
FTY720 (pFTY720) acts on four of the five S1PRs (S1PR1,
S1PR3, S1PR4 and S1PR5) and acts as a functional antag-
onist at the S1PR1 subtype by causing S1PR1 internalisa-
tion, thereby inhibiting lymphocyte egress from lymph
nodes to the periphery and central nervous system (CNS)
[3]. FTY720 can also cross the blood-brain barrier, where it
is then phosphorylated and likely regulates neuronal and
glial cells [4, 5]. S1PR expression is cell-type dependent
and these receptors are known to play a role in, for ex-
ample, astrocyte migration, oligodendrocyte myelination
state and neurite outgrowth and neurogenesis [5–9].* Correspondence: devk@tcd.ie
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Since the development of pFTY720 and its demon-
strated clinical efficacy in MS, there have been ongoing
efforts to develop more selective S1PR agonists and an-
tagonists [10]. These compounds have focused primarily
on creating selectivity for S1PR1 and/or S1PR5, with
limited activity for S1PR3. Reasons for this, in most part,
are due to suggestions that S1PR1 regulates inflamma-
tory response [11], that S1PR1 and S1PR5 can promote
myelination state [4, 12–14], but that S1PR3 activation
induces bradycardia [10, 15]. Siponimod (BAF312) ((E)-
1- (4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)i-
mino)ethyl)-2-ethylbenzyl)azetidine-3-carb oxylic acid))
is a S1PR1/S1PR5 dual agonist that has been developed
by modification of the hydrophobic alkyl chain in FTY720
and replacement of the n-octyl moiety with a substituted
benzyloxy oxime moiety [10]. Further replacement of an
amino phosphate moiety of FTY720 by amino carboxylic
acids has provided BAF312 with shorter elimination half-
lives in vivo and with the added benefit of developing a
‘non’ pro-drug [16]. In rat models of experimental auto-
immune encephalomyelitis (EAE), BAF312 suppresses
preclinical symptoms [16]. Interestingly, however, despite
sparing S1PR3 activity, BAF312 still causes bradycardia in
humans; however, this can be mitigated using a novel
dose titration scheme (up to 2–10 mg over 9/10 days)
[10, 16, 17]. BAF312 has successfully undergone phase
II clinical trials for relapsing remitting MS warranting
further phase III trials [18].
Here, we investigate the effects of BAF312 on S1PR
trafficking, signalling and pro-inflammatory cytokine
levels in astrocytes and microglia, as well as its effects
on demyelination in organotypic slices cultures. We also
demonstrate the effects of BAF312 in a demyelination
slice culture model of globoid cell leukodystrophy
(Krabbe disease, KD) using the toxic lipid metabolite
psychosine.
Methods
Glial and cerebellar slice cultures
Human and mouse astrocytes were cultured as we have
described before [19, 20]. Microglia were prepared as
mixed glia cultures as described [19, 20] and grown in
DMEM/F12 (Fisher) supplemented with 10 % heat inac-
tivated foetal bovine serum (FBS) (Labtech, FB-1090),
1 % penicillin/streptomycin (Sigma, P4333) and M-CSF
(20 ng/ml) and GM-CSF (10 ng/ml). After 12 days in
culture, the microglia were separated from astrocytes by
placing them on a rotating shaker for 2–3 h at room
temperature. The media containing the microglia was
then centrifuged for 3 min at 2000 rpm. The supernatant
was discarded and the resultant pellet resuspended in
1 ml of warmed media. Cells were counted using Bright
line and plated (1 × 105 cells/ml) in 24-well plates and
incubated for 24 h before the addition of warmed
supplemented DMEM. In all cases, before treatments,
the cells were serum starved for 3–4 h by incubating in
serum-free DMEM/F12 at 37 °C and 5 % CO2. Specific
treatment details are indicated in the figure legends.
Organotypic cerebellar slice cultures were prepared exactly
as we have described previously [9, 21]. In brief, tissue iso-
lated from postnatal day 10 (P10) C57BL/6 mice and
400 μm parasagittal slices of cerebellum were grown on cell
culture inserts (five to six slices each) (Millicell PIC-
MORG50 Millipore). Slices were cultured using an inter-
face method with 1 ml of medium per 35 mm well. For the
first 3 days in vitro (DIV), the slices were grown in serum-
based medium (50 % Opti-Mem (Invitrogen), 25 % Hanks’
buffered salt solution (HBSS) (Gibco), 25 % heat-inactivated
horse serum and supplemented with 2 mM Glutamax,
28 mM D-glucose, 100 U/mL penicillin/streptomycin
(Sigma) and 25 mM HEPES, (Sigma) at 35.5 °C and 5 %
CO2. After three DIV, the slices were transferred to
serum-free medium (98 % Neurobasal-A and 2 % B-27
(Invitrogen), supplemented with 2 mM Glutamax, 28 mM
D-glucose, 100 U/mL penicillin/streptomycin and 25 mM
HEPES). Demyelination was induced at 12 DIV and exam-
ined at 14 DIV. All tissue was isolated in accordance with
EU guidelines and protocols approved by the Trinity
College Dublin ethics committee.
Biochemical analysis
For cytokine analysis, supernatants from cell culture were
removed and examined using ELISA for IL6 (DY406) ac-
cording to the manufacturer’s instructions (R&D systems)
and exactly as we have described before [21]. For Western
blotting, astrocytes were scraped from the culture plate
and suspended in PTxE buffer (PBS, 1 % Triton-X, 1 mM
EDTA). Samples were denatured and electrophoresis
carried out on 10 % SDS-polyacrylamide gels exactly as
we have previously reported [21]. Primary antibodies
used were anti-pERK (Millipore, 05-797R), anti-pAKT
(Cell Signalling, S473), anti-ERK 1/2 (Millipore 05-481)
and anti-actin (Abcam, ab3280). Secondary antibody
used was HRP conjugated mouse (Sigma, A8924) or
rabbit (GE Healthcare, NA934).
Calcium signalling
Calcium signalling was performed as previously described
[19, 22]. Briefly, cells were grown until ∼80 % confluency
on glass-bottomed FluoroDishes (World Precision Instru-
ments, Sarasota, FL, USA). Cells were serum starved for
3 h and pre-treated for 1 h with S1PR1 antagonist (NIBR-
0213) [23] or left in serum-free media. The cells were
washed with 1 ml 37 °C HBSS (Invitrogen) supplemented
with 20 mM HEPES buffer (Invitrogen) and 5.5 mM
glucose (Sigma Aldrich). Cells were then loaded with
2 μM Fluo-8 AM (Invitrogen) in supplemented 37 °C
HBSS for 40 min at 37 °C and 5 % CO2. Fluo-8 AM dye
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was removed and cells were washed with 37 °C supple-
mented HBSS. Next, cells were left to rest in 1 ml sup-
plemented HBSS at room temperature in the dark for
20 min. Calcium responses were recorded using an
Olympus FV1000 Confocal Microscope with ×20 lens.
For analysis, images were obtained at a rate of 1 frame/
2 s for a total of 250 s. Images were then analysed using
the Olympus Fluoview viewer software. Fluorescence was
normalised to mean baseline fluorescence (0–30 s) (ΔF/
F0). GraphPad Prism 4 software was used to generate
calcium response traces presented as ΔF/F0 over time.
Immunocytochemistry
Post-treatment mouse astrocytes were washed with PBS
(Sigma Aldrich, UK) and fixed with ice-cold PFA buffer
(3.7 % formaldehyde in PBS, pH 7.4). Cells were washed
in PBS, permeabilised with PTx buffer (0.1 % Triton
X-100 in PBS, pH 7.4) and washed again with PBS.
Non-specific binding was reduced by incubating cells
for 1 h at room temperature in TwB buffer (PBS supple-
mented with 0.1 % Tween 20, 1 % BSA). For all antibody
incubation steps, TwB buffer (PBS supplemented with
0.05 % Tween-20 and 0.5 % BSA) was used. The cells were
incubated overnight at 4 °C with primary antibodies. For
S1PR1 staining, cells were incubated with biotinylated
anti-rabbit (Vector, BA-1000) for 2 h. The cells were then
washed and incubated with Avidin-Alexa 488 coupled
secondary antibody (1/1000 dilution: Invitrogen, S-11223)
and DyLight 549 conjugated anti-mouse (1/1000 dilution:
Jackson Immunoresearch) for a further 45 min. Cells were
washed twice with PBS again and incubated with Hoechst
in PBS for 10 min. Finally, the cells were washed and cov-
erslips mounted onto a drop of Vectorshield on a glass
slide and sealed with nail polish. The cells were visualised
with an Olympus FV1000 scanning confocal. For organo-
typic cerebellar slice cultures, immunostaining was per-
formed as we have described previously [9]. Confocal
images were captured using a LSM 510 Meta microscope
at ×10 or ×20 magnification. These resulting images were
analysed using ImageJ software. A total number of five to
six slices were used per condition, and the fluorescence of
each cerebellar slice was captured using five to six inde-
pendent regions of interest (ROI). The ROI were selected
randomly to cover the whole slice and the mean fluores-
cence was calculated using a total of 25–36 independent
ROI observations, for each independent experiment.
Primary antibodies used were mouse anti-Vimentin
(1/1000 dilution: Santa Cruz sc-373717), rabbit anti-
S1PR1 (1/500 dilution: Santa Cruz sc-25489), rabbit
anti-myelin basic protein (MBP) (1/1000 dilution: Abcam
ab40390) and chicken anti-neurofilament H (NFH) (1/1000
dilution: Millipore, MAB5539). Secondary antibodies used
were DyLight 549 conjugated anti-mouse (1/1000: Jackson
Immunoresearch), Alexa Fluor 488 anti-rabbit (1/1000: Life
Technologies A11008) and Alexa Fluor 633 anti-chicken
(1/1000: Life Technologies A21103).
Statistical analysis
All statistical analysis was performed using Prism 5
GraphPad Software package. A one-way ANOVA with
Newman-Keuls post hoc test was used to compare
groups. The significance levels (or alpha levels) were set
at p < 0.05*, p < 0.01** and p < 0.001***.
Results
Activation of S1PR1/S1PR5 promotes pERK and pAKT
signalling in mouse and human astrocytes
The Ras/Raf/MEK/ERK and PI3K/PTEN/AKT signalling
cascades are key signalling pathways involved in the
regulation of cell survival and proliferation of numerous
cell types. Activation of the S1PRs is known to induce
potent ERK phosphorylation in astrocytes [24] and AKT
phosphorylation in various mammalian cells [25, 26]. In-
duction of pERK is known to be a transient response
with maximal induction of signalling seen between 10
and 30 min of treatment [24]. Here, we investigated the
effect of the S1PR1/S1PR5 agonist, BAF312, on ERK and
AKT phosphorylation in human and mouse astrocytes.
Cultured human and mouse astrocytes were serum
starved for 4 h and then treated with increasing concen-
trations of BAF312 (1 nM, 10 nM, 100 nM and 1 μM)
for 10 min (pERK) or 30 min (pAKT) and the samples
prepared for Western blotting. As expected, the treat-
ment of astrocytes with BAF312 for 10 and 30 min in-
duced ERK and AKT phosphorylation, respectively, in a
concentration-dependent manner in both mouse and
human astrocytes (Fig. 1). These data suggest that a lack
of S1PR3 activity does not impede the ability of BAF312
to regulate ERK and AKT signalling pathways.
Differential roles for S1PR1 and S1PR3 in pERK signalling
in mouse and human astrocytes
Given that astrocytes express S1PR1, S1PR3 and S1PR5,
we examined further the role of these individual recep-
tors to induce pERK and pAKT using selective agonists
and antagonists. In mouse astrocytes, AUY954 treatment
(S1PR1 agonist) induced significant pERK signalling,
with a limited effect observed for CYM5541 treatment
(S1PR3 agonist) (Tocris Bioscience, 4897) and no effect
seen with a selective S1PR5 agonist, herein called UC-
42-WP04 (compound 1 L, [7]) (Fig. 2Ai). Pretreatment
with NIBR-0213 (S1PR1 antagonist) (1 μM) fully inhibited
BAF312-induced pERK (Fig. 2Aii). The data also showed
that pretreatment with NIBR-0213 (S1PR1 antagonist), but
not TY52156 (S1PR3 antagonist), partially blocked
pFTY720-mediated effects (Fig. 2Aiii). In human astrocytes,
AUY954 (S1PR1 agonist) and CYM5541 (S1PR3 agonist)
induced pERK signalling to a similar extent, while UC-42-
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WP04 (S1PR5 agonist) treatment had no effect (Fig. 2Bi).
Pre-treatment with NIBR-0213 (S1PR1 antagonist) com-
pletely inhibited effects of BAF312 (Fig. 2Bii), while pre-
treatment with NIBR-0213 (S1PR1 antagonist) or TY52156
(S1PR3 antagonist) modestly decreased the effects of
pFTY720 on levels of pERK (Fig. 2Biii). Together, these ob-
servations suggest S1PR1 activation, and to a lesser extent,
S1PR3 increases levels of pERK in mouse astrocytes. In
contrast, the activation of S1PR1 or S1PR3 promotes
equally pERK signalling in human astrocytes.
Differential roles for S1PR1 and S1PR3 in pAKT signalling
in mouse and human astrocytes
To further examine the differentially coupling of S1PRs
in mouse and human astrocytes, we also examined the
role of these individual receptors to induce pAKT. In
mouse astrocytes, AUY954 treatment (S1PR1 agonist)
induced significant pAKT signalling, with no effect ob-
served for CYM5541 (S1PR3 agonist) or UC-42-WP04
(S1PR5 agonist) treatment (Fig. 3Ai). Pretreatment with
NIBR-0213 (S1PR1 antagonist) (1 μM) fully inhibited
BAF312-induced pAKT (Fig. 3). We also found that pre-
treatment with NIBR-0213 (S1PR1 antagonist), but not
TY52156 (S1PR3 antagonist), blocked pFTY720-mediated
effects (Fig. 3Aiii). In human astrocytes, AUY954 (S1PR1
agonist) and CYM5541 (S1PR3 agonist) induced pAKT
signalling to a similar extent, while UC-42-WP04 (S1PR5
agonist) treatment had no effect (Fig. 3Bi). Pre-treatment
with NIBR-0213 (S1PR1 antagonist) completed inhibited
effects of BAF312 (Fig. 3Bii), while pre-treatment with
NIBR-0213 (S1PR1 antagonist) or TY52156 (S1PR3 antag-
onist) did not alter the effects of pFTY720 on levels of
pAKT (Fig. 3Biii). Therefore, somewhat different to pERK
signalling, these results suggest that pFTY720 likely in-
creases pAKT signalling via S1PR1 more so than S1PR3,
in mouse astrocytes. In human astrocytes, similar to
pERK, we find S1PR1 and S1PR3 activation equally lead to
an increase in pAKT. Overall, these data suggest that
Fig. 1 Agonism of S1PR1/5 promotes pERK and pAkt signalling in mouse and human astrocytes. BAF312 at concentrations shown induced pERK
after 10 min (n = 3) and pAKT after 30 min treatments (n = 4) a in mouse astrocytes and b in human astrocytes. Data presented as ±SEM (n = 3-4),
one-way ANOVA and Newman-Keuls multiple comparison post-test. *p < 0.05, **p < 0.01, ***p < 0.001
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S1PRs may regulate differentially the signalling pathways
pERK and pAKT in mouse versus human astrocytes.
BAF312 induces internalisation of astrocytic S1PR1
pFTY720 is known to cause internalisation of the S1PR1
and hence is often referred to as a functional antagonist at
this receptor subtype. This feature of functional antagonism
forms the basis pFTY720’s efficacy in the treatment of re-
lapsing remitting MS. Therefore, we investigated whether
the S1PR1/S1PR5-selective agonist, BAF312, also induced
internalisation of the S1PR1. Mouse astrocytes were serum
starved and then treated for 1 h with increasing concentra-
tions of BAF312 (10 nM, 100 nM, 1 μM or 10 μM) as well
as pFTY720 (1 μM). The cells were then stained with anti-
bodies against the astrocytic marker Vimentin and S1PR1.
As previously shown [19, 22, 24], 1 μM pFTY720 induced
internalisation of the S1PR1. Similarly, BAF312 induced a
concentration-dependent internalisation of S1PR1 (Fig. 4).
These data suggest that BAF312 may likely induce transient
S1P1R stimulation followed by long-term functional antag-
onism similar to pFTY720.
BAF312 induces an increase in iCa
2+ levels in human
astrocytes
The endoplasmic reticulum is the major store of Ca2+ in as-
trocytes [27] and activation of S1PRs by pFTY720 and
AUY954 is known to evoke Ca2 signalling in astrocytes [19,
22]. Here, we investigated the effect of the dual S1PR1/
S1PR5 agonist BAF312 on Ca2+ signalling in human astro-
cytes. Human astrocytes were serum starved and loaded
with Fluo-8 AM prior to stimulation with increasing con-
centrations of BAF312 (10 nM, 100 nM, and 1 μM). In
these studies, BAF312 (100 nM and 1 μM) was observed to
elicit an increase in iCa
2+ levels. We also noted a minority
of cells showing Ca2+ oscillations (data not shown). The ef-
fect of BAF312 was abolished by pre-treatment with the
S1PR1 antagonist NIBR-0213 suggesting a role for the
S1PR1 subtype (Fig. 5). These studies further support our
observations that the S1PR1 subtype, compared to S1PR3,
Fig. 2 Differential roles for S1PR1 and S1PR3 in pERK signalling in mouse and human astrocytes. Astrocytes were serum starved for 4 h before all
treatments. All treatment with agonists were for 10 min and pretreatment with antagonists were at 1 μM for 1 h. Ai AUY954 (S1PR1 agonist, 1 μM), but
not CYM5541 (S1PR3 agonist, 1 μM) or UC-42-WP04 (S1PR5 agonist, 1 μM) induced pERK signalling in mouse astrocytes. Bi Similar treatments with AUY954
or CYM5541, but not UC-42-WP04, induced pERK signalling in human astrocytes. Pre-treatment with NIBR-0213 (S1PR1 antagonist) fully blocked BAF312
(100 nM)-induced pERK effects in Aii and Aiii mouse and Bii and Biii human astrocytes. Pre-treatment with TY52156 (S1PR3 antagonist) showed no effect
on pFTY720-mediated increase of pERK in Aiiimouse astrocytes, while Biii partially attenuating pFTY720 (100 nM)-mediated effects in human astrocytes.
Data presented as ±SEM (n = 3–6), one-way ANOVA and Newman-Keuls multiple comparison post-test compared to non-treated control,
*p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.05, ##p < 0.001 compared to FTY720. R1 S1PR1, R3 S1PR3, R5 S1PR5, pan S1PR pan agonist, R1Ant S1PR1
antagonist, R3Ant S1PR3 antagonist
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plays a major role in regulating Ca2+ signalling in astrocytes
[19, 22]. Moreover, similar to our observations for pERK
and pAKT signalling pathways, these data suggest that a
lack of activity on S1PR3 does not preclude BAF312 from
regulating Ca2+ signalling.
S1PR does not robustly attenuate levels of IL6 in
astrocytes
Previous studies from our and other groups have demon-
strated that S1PRs play a role in regulating the levels of cy-
tokines in a number of immune cell cultures and in
organotypic slice cultures [5, 9, 28, 29]. Here, we investi-
gated the modulatory effect of BAF312 on lipopolysacchar-
ide (LPS)- or TNFα/IL17-induced levels of the cytokine
IL6 using isolated mouse and human astrocytes, respect-
ively. Cultured human and mouse astrocytes were serum
starved for 4 h and pre-treated with BAF312 (1 nM,
10 nM, 100 nM and 1 μM) for 1 h. Mouse astrocytes were
then treated with LPS (100 ng/mL) for 18 h while human
astrocytes were treated with TNFα/IL17 (10 ng/ml, 50 ng/
ml) for 18 h, as we have previously described [20, 30]. The
supernatants were then analysed by ELISA (Fig. 6a). LPS
treatment of mouse astrocytes resulted in the increase of
IL6 which, in our hands, was only modestly attenuated by
either pFTY720 or BAF312 (Fig. 6b). Human astrocytes
treated with TNFα/IL17 also resulted in the increase of
IL6, which was also not noticeably altered by either
pFTY720 or BAF312 treatment (Fig. 6c). We additionally
investigated these effects in mouse microglia cultures and
similarly found that LPS induced significant levels of IL6;
however, these effects were again only modestly attenuated
by pFTY720 or BAF312 (Fig. 6d, e). These data demon-
strate that modulation of S1PR by BAF312 or pFTY720
does not strongly alter the levels of IL6 in astrocytes and
microglia, at least in isolated cell cultures.
BAF312 attenuates LPC-induced demyelination in mouse
organotypic cerebellar slice cultures
pFTY720 promotes remyelination as well as limits demye-
lination induced by the bioactive lipid lysolecithin (lyso-
phosphatidylcholine, LPC) [8, 9]. The high expression of
S1PR5 on oligodendrocytes suggests that this receptor
may also have roles in myelination. Therefore, we exposed
organotypic cerebellar slice cultures to LPC (0.5 mg/ml)
Fig. 3 Differential roles for S1PR1 and S1PR3 in pAKT signalling in mouse and human astrocytes. Astrocytes were serum starved for 4 h before all
treatments. All treatment with agonists were for 30 min and pretreatment with antagonists were at 1 μM for 1 h. Ai AUY954 (S1PR1 agonist, 1 μM), but
not CYM5541 (S1PR3 agonist, 1 μM) or UC-42-WP04 (S1PR5 agonist, 1 μM) induced pAKT signalling in mouse astrocytes. Bi Similar treatments
with AUY954 or CYM5541, but not UC-42-WP04, induced pAKT signalling in human astrocytes. Pre-treatment with NIBR-0213 (S1PR1 antagonist) blocked
BAF312 (100nM) in Aii mouse and Bii human astrocytes. Pre-treatment with TY52156 (S1PR3 antagonist) showed no effect on pFTY720 (100 nM)-mediated
increase of pAKT in Aiii mouse astrocytes or Biii human astrocytes. Data presented as ±SEM (n= 3–6), one-way ANOVA and Newman-Keuls multiple
comparison post-test compared to non-treated control *p< 0.05, **p< 0.01, ***p< 0.001, ##p< 0.001 compared to FTY720. R1 S1PR1, R3 S1PR3, R5 S1PR5,
pan S1PR pan agonist, R1Ant S1PR1 antagonist, R3Ant S1PR3 antagonist
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in the presence or absence of BAF312 (10 nM) for 18 h
and treated for a further 30 h with BAF312 (10 nM)
(Fig. 7a). Similar to our previous studies demonstrating
the protective effects of pFTY720 [9, 21], the LPC-
induced demyelination in the cerebellar slice cultures was
attenuated by treatment with BAF312 (53.8 ± 11.1 % vs
97.4 ± 15.5 %) (Fig. 7b). To determine further whether
BAF312 attenuated the levels IL6, the media from these
organotypic slice cultures was analysed by ELISA. LPC
induced at least a 60-fold increase of IL6 after 18 h
(0.03 ± 0.01 ng/ml vs. 1.14 ± 0.4.ng/ml) compared with
controls. Notably, in contrast to its effects in isolated
astrocyte or microglia cell cultures, BAF312 (10 nM)
treatment attenuated the LPC-induced levels of IL6
after 18 h (1.14 ± 0.4 ng/ml vs 0.4 ± 0.04 ng/ml), re-
spectively (Fig. 7c). These effects were transient, where
IL6 returned to high levels after 48 h (not shown).
These findings in slice cultures may be explained by
direct effects of BAF312 on immune cells rather than
on astrocytes or microglia, as we have previously dis-
cussed for pFTY720 [9, 21]. Taken together, these re-
sults demonstrate that more selective S1PR1/S1PR5
compounds, such as BAF312, can significantly attenu-
ate demyelination.
BAF312 attenuates demyelination effects of the Krabbe
disease metabolite, psychosine, in organotypic cerebellar
slice cultures
Rapid and complete loss of myelin and the myelin-forming
oligodendrocytes is one of the main pathological features
of KD [31]. This illness is believed to be caused by the pro-
gressive accumulation of the toxic lipid metabolite, psycho-
sine, in the brains of patients [31]. Recently, we have
shown that pFTY720 significantly attenuates psychosine-
induced demyelination in cerebellar slices [32]. Here, to
corroborate these findings, we examined whether BAF312
could also attenuate psychosine-induced demyelination.
Organotypic cerebellar slice cultures were exposed to psy-
chosine (20 μM) in the presence or absence of BAF312
(10 nM) for 18 h and treated for a further 30 h with
BAF312 (10 nM) (Fig. 8a). We noted that psychosine in-
duced a modest, although not significant, decrease in the
levels of neurofilament H (NFH). More importantly, psy-
chosine induced significant demyelination, as measured by
the loss of MBP staining, which was significantly attenu-
ated by BAF312 (10 nM) (52.7 ± 12.5 % vs 80.3 ± 5.7 %)
(Fig. 8b). We again measured the levels of IL6 by ELISA in
these experiments, after the initial 18-h treatment. In this
case, unlike LPC, psychosine did not induce an increase in
Fig. 4 BAF312 induces internalisation of the S1PR1. Mouse astrocytes were serum starved for 4 h and then treated for 1 h with BAF312 (10 nM,
100 nM, 1 μM) or pFTY (1 μM). BAF312 at 1 μM concentration induced internalisation of S1PR1
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the levels of IL6 (Fig. 8c). We suggest, therefore, that the
modulation of S1PR1/S1PR5 by BAF312 is sufficient to
rescue demyelination associated with or without changes




In this study, we investigated the role S1PR1 and S1PR5 in
astrocyte function by using the S1PR3-sparing drug
BAF312 (Siponimod), which is currently in phase II clinical
Fig. 5 BAF312 induces an increase in iCa
2+ levels in human astrocytes. Stimulation of human astrocytes with the S1P1/S1P5 receptor agonist
BAF312 increases iCa
2+ levels in Fluo-8 AM loaded human astrocytes. a Representative images taken from time-lapse series at baseline and after
addition of BAF312 (30 s) is shown. All cells were stimulated and responded to 3 μM glutamate (150 s) (not shown). b Analysis showing traces of
four separate experiments. c Average data showing BAF312 significantly promotes iCa
2+ levels in human astrocytes, which is attenuated by the
S1PR1-selective antagonist NIBR-0213 (n = 4)
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trials for secondary progressive MS. Similar to pFTY720
[19, 24], we found BAF312 induced levels of pERK, as well
as pAKT, in a concentration-dependent manner in both
human and mouse astrocytes. Furthermore, we demon-
strated that the selective S1PR1 agonist, AUY954, induced
pERK and pAKT signalling in both human and mouse as-
trocytes, the S1PR3 agonist, CYM5541, induced pERK and
pAKT only in human astrocytes and the S1PR5 agonist,
UC-42-WP04, did not induce ERK or AKT phosphoryl-
ation in either mouse or human astrocytes. The S1PR1
specific antagonist, NIBR-0213 [23], inhibited the effects of
BAF312 on pERK and pAKT signalling in human and
mouse astrocytes, suggesting that BAF312-induced pERK
and pAKT is mediated primarily via the S1PR1 subtype.
Using the S1PR1 and S1PR3 antagonists, NIBR-0213 and
TY52156, we showed that S1PR1 played a more critical
role in regulating pAKT signalling compared to pERK in
mouse astrocytes and that both S1PR1 and S1PR3 played
similar roles in pERK and pAKT signalling in human astro-
cytes. BAF312 also stimulated levels of Ca2+ in human as-
trocytes, which was attenuated by NIBR-0213, indicating
further an importance of the S1PR1 subtype. Similar to
pFTY720, the treatment of astrocytes with BAF312 in-
duced S1PR1 internalisation in a concentration-dependent
manner. In our hands, neither pFTY720 nor BAF312
greatly attenuated the release of IL6 from LPS- or TNFα/
IL17-stimulated mouse and human astrocytes, respectively.
In addition, pFTY720 did not attenuate IL6 levels from
LPS-stimulated mouse microglial cultures. We also report
here that BAF312 attenuated both LPC- and psychosine-
Fig. 6 S1PR modulation selectively attenuates TLR4, but not TNFR/IL17R, mediated increase in the levels of IL6 in astrocytes. a Astrocytes or microglia
were serum starved for 4 h, pre-treated with indicated concentrations of BAF312 and then treated with LPS (1–100 ng/ml) or TNFα/IL17. b Mouse
astrocytes treated with LPS increased levels of IL6, which was modestly attenuated by BAF312 (n = 7). c Human astrocytes treated with LPS did not
increase levels of IL6 (data not shown). In agreement with our previous studies, IL17/TNFα increased levels of IL6; however, these were not inhibited by
BAF312 or FTY720 (n = 4). d, e Mouse microglia treated with LPS (1–100 ng/ml) increased IL6 levels in a concentration-dependent manner. pFTY720
and BAF312 moderately attenuated the LPS-induced increases in IL6. Data presented as ±SEM (n = 3–7), one-way ANOVA and Newman-Keuls multiple
comparison post-test *p < 0.05, **p < 0.01, ***p < 0.001
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induced demyelination in organotypic slice cultures. The
effects of BAF312 in LPC-induced demyelination was ac-
companied by a decrease in the induced levels of IL6, in
agreement with our previous study [9]. Of most interest,
the effect of BAF312 in the LPC and psychosine-induced
demyelination was not associated with changes in the levels
of IL6. Overall, these studies suggest that more selective
S1PR compounds such as BAF312 may regulate myelin-
ation state in both inflammatory and non-inflammatory
models of demyelination.
Differential coupling of S1PR subtypes to pERK and pAKT
in mouse and human astrocytes.
The signalling molecules pERK and pAKT are both associ-
ated with activating pro-survival pathways, and S1PRs are
known to modulating these pathways [33–35]. To further
delineate the relative contributions of S1PR1, 3 or 5 to
modulate ERK and AKT phosphorylation in astrocytes, we
used the selective agonists AUY954 (S1PR1), CYM5541
(S1PR3) and UC-42-WP04 (S1PR5) to stimulate human
and mouse astrocytes. We found that S1PR5 is not coupled
to pERK and pAKT in mouse or human astrocytes. In con-
trast, the S1PR1 agonist, AUY954, induced ERK and AKT
phosphorylation in both human and mouse astrocytes
indicating that S1PR1 plays a central role in the induc-
tion of pERK and pAKT. Interestingly, the S1PR3 agon-
ist, CYM5541, induced ERK and AKT phosphorylation
only in human astrocytes suggesting that S1PR3 may
have a greater influence on pERK and pAKT signalling
in human astrocytes in comparison to mouse astro-
cytes. By use of the S1PR1 antagonist, NIBR-0213 and
the S1PR3 antagonist, TY52156, we also demonstrated the
following rank order of importance for pFTY720 activa-
tion of pERK and pAKT in human and mouse astrocytes:
S1PR1 > S1PR3 for pERK signalling and S1PR1 >> S1PR3
for pAKT signalling in mouse astrocytes; S1PR3 ≥ S1PR1
Fig. 7 BAF312 attenuates LPC-induced demyelination and IL-6 levels in mouse organotypic cerebellar slice cultures. A Experimental timeline is shown,
as previously described [9]. Organotypic cerebellar slice cultures were treated with LPS (0.5 mg/ml) for 18 h in the presence or absence of BAF312 and
then treated with BAF213 alone for an additional 30 h (totalling 48 h) after which slices were processed for immunostaining. Bi Representative images
show BAF312 attenuates LPC-induced demyelination as measured by MBP immunostaining, with limited effects on NFH immuoreactivity. Bii, Biii Data
analysis of three separate experiments, demonstrating effects of BAF312 on LPC-induced changes in MBP and NFH immunostaining. C Organotypic
cerebellar slice cultures were treated with LPS (0.5 mg/ml) for 18 h in the presence or absence of BAF312, and the media was processed for ELISA.
Treatment with BAF312 attenuated the levels of IL6. Data presented as ±SEM (n= 3–4), one-way ANOVA and Newman-Keuls multiple comparison
post-test. *p< 0.05, **p < 0.01, #p < 0.05 compared to LPC
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for pERK signalling and S1PR1 = S1PR3 for pAKT sig-
nalling in human astrocytes. Such species-dependent
differences between human and mouse S1PR1 and
S1PR3 function has been reported before. For example,
a variance in S1PR1 and S1PR3 function between hu-
man and mouse has been seen previously as the initial
bradycardia experienced after pFTY720/BAF312 treat-
ment is reported to be species-dependent [10, 16]. In
addition, bone marrow-derived mesenchymal stem cells
(MSCs) have been shown to express collagen via the
activation of S1PR1 and S1PR3 in mouse cells, while
collagen expression MSCs is negatively regulated by
S1PR1 and S1PR3 in human cells (Yang et al. [36]).
In summary, our results suggest that S1PR1, compared
to S1PR3, plays a more dominant role in pERK/pAKT
signalling in mouse astrocytes, whereas S1PR1 and
S1PR3 are equally important in regulating these path-
ways human astrocytes.
The role of S1PRs in regulating levels of IL6 in microglia
and astrocytes
Specific knockout of S1PR1 from astrocytes or pFTY720
treatment reduces the levels of IL1β, IL6 and IL17,
which are cytokines increased during the course of EAE
[5]. In agreement, pFTY720 attenuates the levels of cyto-
kines such as IL6, TNFα and IL1β from LPS-activated
microglia, in addition to enhancing the levels of brain-
derived nerve factor (BDNF) and glial-derived nerve fac-
tor (GDNF) [37]. Treatment of organotypic cerebellar
slice cultures with LPC for 2 days also increases the
number of both Iba1+ and GFAP+ cells, which subsides
after 14 days of LPC treatment, suggesting a temporal ef-
fect of LPC on microglia and astrocyte cells numbers [8].
The treatment of these slice cultures with pFTY720 alone
does not appear to alter astrocyte levels [9], but treatment
with pFTY720 after a 2-day exposure to LPC increases the
number of Iba1+ and GFAP+ cells, compared to LPC
Fig. 8 BAF312 attenuates psychosine induced demyelination in mouse organotypic cerebellar slice cultures. A Experimental timeline is shown.
Organotypic cerebellar slice cultures were treated with psychosine (20 μM) for 18 h in the presence or absence of BAF312 and then treated with
BAF213 alone for an additional 30 h (totalling 48 h) after which slices were processed for immunostaining. Bi Representative images show BAF312
attenuates psychosine-induced decrease in MBP immunostaining, with limited effects on NFH immunoreactivity. Bii, Biii Data analysis of four separate
experiments, demonstrating effects of BAF312 on pyschosine-induced changes in MBP and NFH immunostaining. C Organotypic cerebellar
slice cultures were treated with pyschosine (20 μM) for 18 h in the presence or absence of BAF312, and the media was processed for ELISA.
Treatment with pyschosine, with or without BAF312, showed no changes in the levels of IL6. Data presented as ±SEM (n = 4)
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alone [8]. Importantly, both treatment with pFTY720 at
the same time as LPC [9] and 2 days after LPC [8] shows
increased levels of myelination compared to LPC alone,
suggesting that pFTY720 can likely inhibit processes of
demyelination and promote events enhancing remyelina-
tion. Here, we showed that while BAF312 and pFTY720
modestly attenuate the levels of IL6 from LPS-stimulated
mouse astrocytes, they had no observable effect on TNFα/
IL17 stimulated human astrocytes. We also found that
pFTY720 did not strongly attenuate LPS-induced IL6 in
cultured mouse microglia. In contrast, BAF312 attenuated
the levels of IL6 levels in organotypic slice cultures treated
with LPC, similar to our previous data [9]. Unlike isolated
cell cultures, organotypic slice cultures preserve the brain
architecture and also contain immune cells [9, 38, 39].
Thus, one possible explanation for our findings using cul-
tured astrocytes and microglia, versus organotypic slice
cultures, may be the absence or presence of peripheral im-
mune cells, respectively. It remains unclear, however, the
number(s) or type(s) of immune cells in these slice cul-
tures that are required to confer a BAF312 effect, if any. A
small and undetectable number of immune cells in these
slices may indeed be sufficient to trigger a subsequent
amplified response by glial cells. The idea that immune
cells can induce demyelination and that S1PR drugs can
attenuate this response is in line with our previous find-
ings demonstrating that MOG-reactive splenocytes can
induce demyelination when added to organotypic slice
cultures and their treatment with pFTY720 reverses this
effect [21].
The potential use of S1PRs as drug targets in Krabbe
disease
The treatment of organotypic slices with the demyelinat-
ing agent LPC is an established in vitro model to study
the effects demyelination, where drugs such as pFTY720
have shown to be protective [8, 9]. In the present study,
we found that BAF312 attenuated both LPC-induced de-
myelination as well as the levels of IL6 in organotypic
slice cultures, similar to that observed for pFTY720 [32].
We also used the toxic agent psychosine to induce de-
myelination, which accumulates in the brain of patients
with KD causing widespread demyelination and almost
complete loss of oligodendrocytes in the white matter
[31]. Notably, we have found that psychosine induces
demyelination in a manner that is not associated with al-
tered levels of cytokines, including IL1β, TNFα and IL6
[32]. Psychosine induced demyelination that was not as-
sociated with altered levels of IL6 as we have previously
observed [32], and most importantly, BAF312 attenuated
this psychosine-induced demyelination. Overall, these
studies suggest that S1PR modulation is protective in
both inflammatory and non-inflammatory models of
demyelination.
Conclusions
The clinical success of pFTY720 in the treatment of
relapsing remitting MS demonstrated the therapeutic
potential of S1PR modulation and prompted efforts to
develop more specific agonists for these receptors. Mod-
ulators with selectivity towards S1PR1 and S1PR5
seemed of particular interest as preclinical observations
in mice suggested that S1PR3 may be responsible for the
transient bradycardia experienced after the first dose of
pFTY720 [10, 15]. Furthermore, S1PR1 modulation plays
a key role in lymphocyte migration [40] and S1PR5 is
expressed on oligodendrocytes where it plays a role in
myelination [7, 8, 13]. This has led to the synthesis of
the dual S1PR1/S1PR5 agonist: BAF312 (Siponimod).
Similar to pFTY720, BAF312 has been reported to
supress pre-clinical symptoms in animal models of EAE.
This drug also selectively decreases T cells (CD4+, naive
and central memory) and B cells in healthy human
volunteers, while sparing effector memory T cells [16].
In a phase II clinical study for relapsing remitting MS,
BAF312 reduced brain MRI lesions up to 80 % in
comparison with placebo control [18]. Bradycardia is
also observed with BAF312, but can be mitigated with a
dose titration regimen [17], thus providing additional
benefits. Importantly, BAF312 is currently undergoing a
phase III trial to investigate its efficacy in patients with
the chronic secondary progressive MS, a disease in
which there is a particular lack of treatments [41]. Given
that pFTY720 has shown limited beneficial effects in
patients with the chronic primary progressive MS (Clini-
calTrials.gov:NCT00731692) and limited effect in second-
ary progressive EAE [42], the outcome of these clinical
trials with BAF312 are highly awaited. In addition to the
differences between primary and secondary progressive
MS, differential effects of the two drugs on human astro-
cytes, which are not observed in mouse astrocytes, might
influence the clinical outcome of the two drugs in pro-
gressive MS.
Here, we demonstrated that BAF312 regulates a number
of signalling pathways in human and mouse astrocytes. In
addition, this compound attenuated demyelination in orga-
notypic slice cultures induced by LPC and by psychosine, a
toxic metabolite that accumulates in the brains of patients
with KD. These findings suggest that the S1PR drugs such
as BAF312 may have utility beyond MS, in a range of de-
myelinating diseases such as KD, for which no therapies
currently exist.
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